

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent of Kathleen C. M. Campbell

Patent No. 7,071,230

Issued July 4, 2006

Confirmation No. 2942

For THERAPEUTIC USE OF D-METHIONINE TO REDUCE THE
TOXICITY OF NOISE

February 23, 2007

REQUEST FOR EXPEDITED ISSUANCE
OF CERTIFICATE OF CORRECTION UNDER 37 CFR 1.322

TO THE COMMISSIONER FOR PATENTS,

SIR:

On studying the above-identified patent, the following errors, apparently made by the Patent and Trademark Office, were found (these errors are also noted on the attached form PTO-1050):

On the Face of the patent, (75) Inventor: "Kathleen C.M. Cambpell" should read -- Kathleen C. M. Campbell --. (See ADS filed 07/23/2001; see executed Declaration filed October 9, 2001).

On page 3 of the patent, second column, "Molteni, F., et al. "Stimulation postirradiation recovery of rat haemopoiesis by a cobalt preparation," *Database Biosis Biosciences Information Service*, Philadelphia, Pennsylvania, Abstract No. 08095385 (See also *Radiobiologia*, vol. 31, No. 6 pp. 835-837, 1991)." should read -- Molteni, F., et al. "The Use of S-adenosyl-methionine as a radioprotective agent" *Gazette Medica Italiana*, 1978, Vol. 137, No. 7-8, pgs. 303-308. --. (See page 7, cite 73, of the Information Disclosure Statement filed 10/9/2001).

In column 29, claim 17, line 7, "The method" should read -- A method --. (See Amendment C dated 01/14/2005, page 4, claim 38).

In column 29, claim 20, line 25-29, replace the text with amended claim 41 of Amendment C dated 01/14/2005 as follows:

-- 20. The method as set forth in claim 17, further comprising administering to said patient a supplemental amount of said otoprotective agent after the administration of said effective amount, the administration of said supplemental amount of said otoprotective agent being sufficient to maintain a blood serum level of otoprotective agent within said patient of from about 20% to about 70% of the blood serum level achieved by administration of the effective amount of said otoprotective agent. --.
(See Amendment C dated 01/14/2005, page 5, claim 41 and Examiner's claim Index dated 09/07/05).

In column 29, claim 21, lines 30-32, replace the text with amended claim 57 of Amendment C dated 01/14/2005 as follows:

-- 21. A method for preventing or treating ototoxicity in a patient exposed to noise for a time and at an intensity sufficient to result in ototoxicity, comprising administering to said patient an anti-ototoxic effective amount of an otoprotective agent comprising methionine; provided that, at the time said otoprotective agent is administered, an antineoplastic effective dose of cisplatin has not been administered or prescribed for administration to said patient. --.
(See Amendment C dated 01/14/2005, page 5, claim 57 and Examiner's claim Index dated 09/07/05).

In column 29, claim 22, lines 33-34, replace the text with amended claim 58 of Amendment C dated 01/14/2005 as follows:

-- 22. The method as set forth in claim 21 wherein said otoprotective agent is selected from the group consisting of D-methionine, L-methionine, D,L-methionine, a pharmaceutically acceptable salt thereof and a combination thereof. --.
(See Amendment C dated 01/14/2005, pages 5-6, claim 58 and Examiner's claim Index dated 09/07/05).

In column 29, claim 23, lines 35-36, replace the text with amended claim 59 of Amendment C dated 01/14/2005 as follows:

-- 23. The method as set forth in claim 21, wherein said otoprotective agent is D-methionine. --.

(See Amendment C dated 01/14/2005, page 6, claim 59 and Examiner's claim Index dated 09/07/05).

In column 29, claim 24, lines 37-39, replace the text with amended claim 60 of Amendment C dated 01/14/2005 as follows:

-- 24. The method as set forth in claim 21, wherein said otoprotective agent is administered prior to said noise exposure. --.

(See Amendment C dated 01/14/2005, page 6, claim 60 and Examiner's claim Index dated 09/07/05).

In column 29, claim 25, lines 40-42, replace the text with amended claim 61 of Amendment C dated 01/14/2005 as follows:

-- 25. The method as set forth in claim 21, wherein said otoprotective agent is administered simultaneously with said noise exposure. --.

(See Amendment C dated 01/14/2005, page 6, claim 61 and Examiner's claim Index dated 09/07/05).

In column 29, claim 26, lines 43-45, replace the text with amended claim 62 of Amendment C dated 01/14/2005 as follows:

-- 26. The method as set forth in claim 21, wherein said otoprotective agent is administered subsequently to said noise exposure. --.

(See Amendment C dated 01/14/2005, page 6, claim 62 and Examiner's claim Index dated 09/07/05).

In column 29, claim 27, lines 46-49, replace the text with amended claim 63 of Amendment C dated 01/14/2005 as follows:

-- 27. The method as set forth in claim 21, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 336 hours before to about 336 hours after said exposure to noise. --.
(See Amendment C dated 01/14/2005, page 6, claim 63 and Examiner's claim Index dated 09/07/05).

In column 29, claim 28, lines 50-53, replace the text with amended claim 64 of Amendment C dated 01/14/2005 as follows:

-- 28. The method as set forth in claim 27, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 48 hours before to about 48 hours after said exposure to noise. --.
(See Amendment C dated 01/14/2005, page 6, claim 64 and Examiner's claim Index dated 09/07/05).

In column 29, claim 29, lines 54-56, replace the text with amended claim 65 of Amendment C dated 01/14/2005 as follows:

-- 29. The method as set forth in claim 24, wherein said otoprotective agent is administered orally, parenterally, or topically to the round window membrane. --.
(See Amendment C dated 01/14/2005, page 6, claim 65 and Examiner's claim Index dated 09/07/05).

In column 30, claim 30, lines 1-6, replace the text with amended claim 66 of Amendment C dated 01/14/2005 as follows:

-- 30. The method as set forth in claim 29, wherein the administration of said effective amount of said otoprotective agent results in a blood serum level equivalent to that achieved by parenteral administration in the range of from about 10 mg/kg body weight to about 400 mg/kg body weight. --.
(See Amendment C dated 01/14/2005, page 7, claim 66 and Examiner's claim Index dated 09/07/05).

In column 30, claim 31, lines 7-10, replace the text with amended claim 67 of Amendment C dated 01/14/2005 as follows:

-- 31. The method as set forth in claim 21, further comprising administering to said patient a supplemental amount of said otoprotective agent after the administration of said effective amount. --.

(See Amendment C dated 01/14/2005, page 7, claim 67 and Examiner's claim Index dated 09/07/05).

In column 30, claim 32, lines 11-16, replace the text with amended claim 68 of Amendment C dated 01/14/2005 as follows:

-- 32. The method as set forth in claim 31, wherein said supplemental amount of said otoprotective agent is administered orally, parenterally, or topically to the round window membrane of said patient. --.

(See Amendment C dated 01/14/2005, page 7, claim 68 and Examiner's claim Index dated 09/07/05).

In column 30, claim 33, lines 17-20, replace the text with amended claim 69 of Amendment C dated 01/14/2005 as follows:

-- 33. The method as set forth in claim 32, wherein the administration of said supplemental amount of said otoprotective agent is sufficient to maintain an effective blood serum level of the otoprotective agent in said patient for a period of from one to fourteen days after the administration of said effective amount. --.

(See Amendment C dated 01/14/2005, page 7, claim 69 and Examiner's claim Index dated 09/07/05).

In column 30, claim 34, lines 21-24, replace the text with amended claim 70 of Amendment C dated 01/14/2005 as follows:

-- 34. The method as set forth in claim 32, wherein the administration of said supplemental amount of said otoprotective agent is sufficient to maintain a blood serum level of otoprotective agent within said patient of from about 20% to about 70% of the

blood serum level achieved by administration of the effective amount of said otoprotective agent. --.

(See Amendment C dated 01/14/2005, page 7, claim 70 and Examiner's claim Index dated 09/07/05).

In column 30, claim 35, lines 25-31, replace the text with amended claim 71 of Amendment C dated 01/14/2005 as follows:

-- 35. A method for preventing or treating ototoxicity in a patient exposed to noise for a time and at an intensity sufficient to result in ototoxicity, the method comprising administering to said patient an effective amount of an otoprotective agent comprising D-methionine, L-methionine, D,L-methionine, a combination thereof or a pharmaceutically acceptable salt thereof, the administration of said effective amount of said otoprotective agent resulting in a blood serum level equivalent to that achieved by parenteral administration in the range of from about 10 mg/kg body weight to about 400 mg/kg body weight, provided that, at the time said otoprotective agent is administered, an antineoplastic effective dose of cisplatin has not been administered or prescribed for administration to said patient. --.

(See Amendment C dated 01/14/2005, pages 7-8, claim 71 and Examiner's claim Index dated 09/07/05).

In column 30, claim 36, lines 32-37, replace the text with amended claim 72 of Amendment C dated 01/14/2005 as follows:

-- 36. The method as set forth in claim 35, wherein said otoprotective agent is administered parenterally, orally or topically to the round window membrane of said patient. --.

(See Amendment C dated 01/14/2005, page 8, claim 72 and Examiner's claim Index dated 09/07/05).

In column 30, claim 37, lines 38-43, replace the text with amended claim 73 of Amendment C dated 01/14/2005 as follows:

-- 37. The method as set forth in claim 35, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 336 hours before to about 336 hours after said exposure to noise. --.
(See Amendment C dated 01/14/2005, page 8, claim 73 and Examiner's claim Index dated 09/07/05).

In column 30, claim 38, lines 44-54, replace the text with amended claim 74 of Amendment C dated 01/14/2005 as follows:

-- 38. The method as set forth in claim 35, further comprising administering to said patient a supplemental amount of said otoprotective agent after the administration of said effective amount, the administration of said supplemental amount of said otoprotective agent being sufficient to maintain a blood serum level of otoprotective agent within said patient of from about 20% to about 70% of the blood serum level achieved by administration of the effective amount of said otoprotective agent. --.
(See Amendment C dated 01/14/2005, page 8, claim 74 and Examiner's claim Index dated 09/07/05).


REMARKS

In accordance with 37 CFR 1.322, a copy of Amendment C, dated January 14, 2005, a copy of the Information Disclosure Statement filed October 9, 2001 and a copy of the Examiner's claim summary dated September 7, 2005 are attached.

Generally, claims 1-19 of the printed patent were printed correctly, but claims 20-38 of the printed patent were not printed as the Examiner intended because they did not correspond to Amendment C dated 01/14/2005 and the Examiner's claim summary dated September 7, 2005.

We respectfully request that a certificate of correction be issued.

Respectfully submitted,

A handwritten signature in black ink, reading "Janet S. Hendrickson", with a stylized flourish at the end.

Janet S. Hendrickson, Ph.D., Reg. No. 55,258
SENNIGER POWERS
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 1 of 5

PATENT NO : 7,071,230
APPLICATION NO.: 09/911,195
ISSUE DATE : July 4, 2006
INVENTOR(S) : Kathleen C.M. Campbell

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the title page:

(75) Inventor: "Kathleen C.M. Cambpell" should read -- Kathleen C. M. Campbell --.

On page 3 of the patent, second column:

"Molteni, F., et al". should read -- Molteni, F., et al. "The Use of S-adenosyl-methionine as a radioprotective agent" *Gazette Medica Italiana*, 1978, Vol. 137, No. 7-8, pgs. 303-308. --.

Column 29:

Claim 17, line 7, "The method" should read -- A method --.

Claim 20 should read:

-- 20. The method as set forth in claim 17, further comprising administering to said patient a supplemental amount of said otoprotective agent after the administration of said effective amount, the administration of said supplemental amount of said otoprotective agent being sufficient to maintain a blood serum level of otoprotective agent within said patient of from about 20% to about 70% of the blood serum level achieved by administration of the effective amount of said otoprotective agent. --.

Claim 21 should read:

-- 21. A method for preventing or treating ototoxicity in a patient exposed to noise for a time and at an intensity sufficient to result in ototoxicity, comprising administering to said patient an anti-ototoxic effective amount of an otoprotective agent comprising methionine; provided that, at the time said otoprotective agent is administered, an antineoplastic effective dose of cisplatin has not been administered or prescribed for administration to said patient. --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Janet S. Hendrickson, Ph.D.
Senniger Powers
One Metropolitan Square
16th Floor
St. Louis, Missouri 63102

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 2 of 5

PATENT NO : 7,071,230
APPLICATION NO.: 09/911,195
ISSUE DATE : July 4, 2006
INVENTOR(S) : Kathleen C.M. Campbell

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 29 continued:

Claim 22 should read:

-- 22. The method as set forth in claim 21 wherein said otoprotective agent is selected from the group consisting of D-methionine, L-methionine, D,L-methionine, a pharmaceutically acceptable salt thereof and a combination thereof. --.

Claim 23 should read:

-- 23. The method as set forth in claim 21, wherein said otoprotective agent is D-methionine. --.

Claim 24 should read:

-- 24. The method as set forth in claim 21, wherein said otoprotective agent is administered prior to said noise exposure. --.

Claim 25 should read:

-- 25. The method as set forth in claim 21, wherein said otoprotective agent is administered simultaneously with said noise exposure. --.

Claim 26 should read:

-- 26. The method as set forth in claim 21, wherein said otoprotective agent is administered subsequently to said noise exposure. --.

Claim 27 should read

-- 27. The method as set forth in claim 21, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 336 hours before to about 336 hours after said exposure to noise. --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Janet S. Hendrickson, Ph.D.
Senniger Powers
One Metropolitan Square
16th Floor
St. Louis, Missouri 63102

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 3 of 5

PATENT NO : 7,071,230
APPLICATION NO.: 09/911,195
ISSUE DATE : July 4, 2006
INVENTOR(S) : Kathleen C.M. Campbell

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 29 continued:

Claim 28 should read:

-- 28. The method as set forth in claim 27, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 48 hours before to about 48 hours after said exposure to noise. --.

Claim 29 should read:

-- 29. The method as set forth in claim 24, wherein said otoprotective agent is administered orally, parenterally, or topically to the round window membrane. --.

Column 30

Claim 30 should read:

-- 30. The method as set forth in claim 29, wherein the administration of said effective amount of said otoprotective agent results in a blood serum level equivalent to that achieved by parenteral administration in the range of from about 10 mg/kg body weight to about 400 mg/kg body weight. --.

Claim 31 should read:

-- 31. The method as set forth in claim 21, further comprising administering to said patient a supplemental amount of said otoprotective agent after the administration of said effective amount. --.

Claim 32 should read:

-- 32. The method as set forth in claim 31, wherein said supplemental amount of said otoprotective agent is administered orally, parenterally, or topically to the round window membrane of said patient. --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Janet S. Hendrickson, Ph.D.
Senniger Powers
One Metropolitan Square
16th Floor
St. Louis, Missouri 63102

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 4 of 5

PATENT NO : 7,071,230
APPLICATION NO.: 09/911,195
ISSUE DATE : July 4, 2006
INVENTOR(S) : Kathleen C.M. Campbell

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 30 continued:

Claim 33 should read:

-- 33. The method as set forth in claim 32, wherein the administration of said supplemental amount of said otoprotective agent is sufficient to maintain an effective blood serum level of the otoprotective agent in said patient for a period of from one to fourteen days after the administration of said effective amount. --.

Claim 34 should read:

-- 34. The method as set forth in claim 32, wherein the administration of said supplemental amount of said otoprotective agent is sufficient to maintain a blood serum level of otoprotective agent within said patient of from about 20% to about 70% of the blood serum level achieved by administration of the effective amount of said otoprotective agent. --.

Claim 35 should read:

-- 35. A method for preventing or treating ototoxicity in a patient exposed to noise for a time and at an intensity sufficient to result in ototoxicity, the method comprising administering to said patient an effective amount of an otoprotective agent comprising D-methionine, L-methionine, D,L-methionine, a combination thereof or a pharmaceutically acceptable salt thereof, the administration of said effective amount of said otoprotective agent resulting in a blood serum level equivalent to that achieved by parenteral administration in the range of from about 10 mg/kg body weight to about 400 mg/kg body weight, provided that, at the time said otoprotective agent is administered, an antineoplastic effective dose of cisplatin has not been administered or prescribed for administration to said patient. --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Janet S. Hendrickson, Ph.D.
Senniger Powers
One Metropolitan Square
16th Floor
St. Louis, Missouri 63102

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 5 of 5

PATENT NO : 7,071,203
APPLICATION NO.: 09/911,195
ISSUE DATE : July 4, 2006
INVENTOR(S) : Kathleen C.M. Campbell

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 30 continued:

Claim 36 should read:

-- 36. The method as set forth in claim 35, wherein said otoprotective agent is administered parenterally, orally or topically to the round window membrane of said patient. --.

Claim 37 should read:

-- 37. The method as set forth in claim 35, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 336 hours before to about 336 hours after said exposure to noise. --.

Claim 38 should read:

-- 38. The method as set forth in claim 35, further comprising administering to said patient a supplemental amount of said otoprotective agent after the administration of said effective amount, the administration of said supplemental amount of said otoprotective agent being sufficient to maintain a blood serum level of otoprotective agent within said patient of from about 20% to about 70% of the blood serum level achieved by administration of the effective amount of said otoprotective agent. --.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Janet S. Hendrickson, Ph.D.
Senniger Powers
One Metropolitan Square
16th Floor
St. Louis, Missouri 63102

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

INVENTOR INFORMATION

Inventor One Given Name:: Kathleen C.M.
Family Name:: Campbell
Postal Address Line One:: P.O. Box 19230
City:: Springfield
State or Province:: IL
Postal or Zip Code:: 62794-9230
City of Residence:: Glenarm
State or Prov. of Residence:: IL
Country of Residence:: US
Citizenship Country:: US

CORRESPONDENCE INFORMATION

Correspondence Customer Number:: 000321

APPLICATION INFORMATION

Title Line One:: THERAPEUTIC USE OF D-METHIONINE TO
Title Line Two:: REDUCE THE TOXICITY OF NOISE
Total Drawing Sheets:: 6
Formal Drawings:: Yes
Application Type:: Continuation in Part
Docket Number:: SIU 7396

REPRESENTATIVE INFORMATION

Representative Customer Number:: 000321

CONTINUITY INFORMATION

This application is a:: Continuation in Part of
Application One:: S.N. 09/057,065
Filing Date:: April 8, 1998

which is a:: Continuation in Part of
Application Two:: Patent No. 6,187,817



#3

Attorney's Docket No. SIU 7396

DECLARATION AND POWER OF ATTORNEY

REGULAR OR DESIGN APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

THERAPEUTIC USE OF D-METHIONINE
TO REDUCE THE TOXICITY OF NOISE

the specification of which:

(check one)

[] is attached hereto

[X] was filed on July 23, 2001 as Application Serial No. 09/911,195, and was amended on _____.

[] was described and claimed in PCT International Application No. _____, filed on _____ and as amended under PCT Article 19 on _____, if any.

ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a) - (d) or §365(b) of any foreign application for patent or inventor's certificate, or §365(a) of any PCT application which designates at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)

Priority Not Claimed

ANY FOREIGN APPLICATION(S), ON THE SAME SUBJECT MATTER WHICH HAS A FILING DATE EARLIER THAN THE EARLIEST APPLICATION FROM WHICH PRIORITY IS CLAIMED

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)
-------------------	--------------------	---------------------------------

CLAIM FOR BENEFIT OF PROVISIONAL APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
_____ (Application Number)	_____ (Filing Date)

**CLAIM FOR BENEFIT OF EARLIER U.S. APPLICATION(S)
UNDER 35 U.S.C. 120**

(complete this part only if this is a divisional,
continuation or CIP application)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

<u>09/057,065</u> (Serial No.)	<u>April 8, 1998</u> (Filing Date)	<u>Issue fee paid May 7, 2001</u> (Status)
<u>08/942,845</u> (Serial No.)	<u>October 2, 1997</u> (Filing Date)	<u>Patent No. 6,187,817</u> (Status)

POWER OF ATTORNEY

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Irving Powers (15,700), Donald G. Leavitt (17,626), John K. Roedel, Jr. (25,914), Michael E. Godar (28,416), Edward J. Hejlek (31,525), William E. Lahey (26,757), Richard G. Heywood (18,224), Frank R. Agovino (27,416), Kurt F. James (33,716), G. Harley Blosser (33,650), Paul I. J. Fleischut (35,513), Vincent M. Keil (36,838), Robert M. Evans, Jr. (36,794), Robert M. Bain (36,736), Kathleen M. Petrillo (35,076), David E. Crawford, Jr. (38,118), Richard L. Bridge (40,529), Christopher M. Goff (41,785), Derick E. Allen (43,468), Matthew L. Cutler (43,574), Michael G. Munsell (43,820), Karen Y. Hui (44,785), Anthony R. Kinney (44,834), Brian P. Klein (44,837), Sarah J. Chickos (46,157), Donald W. Tuegel (45,424), Steven M. Ritchey (46,321), Michael J. Thomas (39,857), Kathryn J. Doty (40,593), Laura R. Polcyn (47,000), James J. Barta, Jr. (47,409), John M. Bodenhausen (47,432), James E. Davis (47,516), Richard A. Schuth (47,929), Debra D. Nye (P-48,260), and Jennifer E. Cook (P-48,330), all of the law firm of SENNIGER, POWERS, LEAVITT & ROEDEL, One Metropolitan Square, 16th Floor, St. Louis, Missouri 63102.

Send Correspondence To:

Direct Telephone Calls To:

Customer Number: 000321

James E. Davis
(314) 231-5400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Kathleen C.M. Campbell

Inventor's signature Kathleen C.M. Campbell Date 9/4/01

Residence Glenarm, Illinois Citizenship US

Post Office address P.O. Box 19230

Springfield, IL 62794-9230

PTO/SB/08A

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number

09/911,195

Filing Date

July 23, 2001

Confirmation Number

2942

First Named Inventor

Kathleen C.M. Campbell

Group Art Unit

1614

Attorney Docket No.

SIU 7396

1

of

8

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
<i>L</i>	1	2,732,400		Weiss	01/24/1956
<i>906</i>	2	4,426,372		Borch	01/17/1984
<i>906</i>	3	5,002,755		Mitchell, et al.	03/26/1991
<i>906</i>	4	5,292,773		Hirsch, et al.	03/08/1994
<i>906</i>	5	5,430,064		Hirsch, et al.	07/04/1995
<i>906</i>	6	5,466,678		Kawabata, e tal.	11/14/1995
<i>906</i>	7	6,177,434		Kopke, et al.	01/23/2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
<i>L</i>	8		06 200 04 A1		Fuji Kagaku Kogyo Kabushiki Kaisha	10/19/1994	

Examiner
SignatureDate
Considered

9/30/02


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/911,195
				Filing Date	July 23, 2001
				Confirmation Number	2942
				First Named Inventor	Kathleen C.M. Campbell
				Group Art Unit	1614
Sheet	2	of	8	Attorney Docket No.	SIU 7396

OTHER ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
9	9	W. WESLEY ALDEN, ET AL., "Exacerbation of Cisplatin-Induced Nephrotoxicity by Methionine," <u>Chem.-Biol. Interactions</u> , 1984, 48, Pgs. 121-124		
9	10	MARK A. BASINGER, ET AL., "Dithiocarbamate-Induced Biliary Platinum Excretion and the Control of cis-Platinum Nephrotoxicity," <u>Toxicology and Applied Pharmacology</u> , 1989, 97, Pgs. 279-288		
9	11	MARK A. BASINGER, ET AL., "L-Methionine Antagonism of cis-Platinum Nephrotoxicity," <u>Toxicology and Applied Pharmacology</u> , 1990, 108, Pgs. 1-15		
9	12	MARK A. BASINGER, ET AL., "L-Methionine Suppresses Pathological Sequelae of cis-Platinum in the Rat." <u>Fundamental and Applied Toxicology</u> , 1990, 14, Pgs. 568-577		
9	13	PIETER J. BOOGAARD, ET AL., "4-Methylthiobenzoic Acid Reduces Cisplatin Nephrotoxicity In Rats Without Compromising Anti-Tumor Activity, <u>Biochemical Pharmacology</u> , 1991, Vol. 41, No. 12, Pgs. 1997-2003		
9	14	PIETER J. BOOGAARD, ET AL., "The Role of Methallothionein in the Reduction of Cisplatin-Induced Nephrotoxicity by Bi ³⁺ -Pretreatment in the Rat <i>In Vivo</i> and <i>In Vitro</i> , Are Antioxidant Properties of Methallothionein More Relevant than Platinum Binding?", <u>Biochemical Pharmacology</u> , 1991, Vol. 41, No. 3, Pgs. 369-375		
9	15	JOSEPH H. BURCHENAL, ET AL., "Studies of Cross-Resistance, Synergistic Combinations and Blocking of Activity of Platinum Derivates," <u>Biochimie</u> , 1978, 60, No. 9, Pgs. 961-965		
	16	KATHLEEN C.M. CAMPBELL, ET AL., "A Review of Cisplatin-Protective Agents Emphasizing Nephro- and Otoprotectants," <u>Proposed Review Article Not Yet Submitted for Publication, Including Additional Reference Lists</u> <i>No date</i>		
9	17	KATHLEEN C.M. CAMPBELL, ET AL., "D-Methionine Provides Excellent Protection from Cisplatin Ototoxicity in the Rat," <u>Hearing Research</u> , 1996, 102, Pgs. 90-98		













Examiner Signature		Date Considered	9/30/02
--------------------	---	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/911,195
				Filing Date	July 23, 2001
				Confirmation Number	2942
				First Named Inventor	Kathleen C.M. Campbell
				Group Art Unit	1614
Sheet	3	of	8	Attorney Docket No.	SIU 7396

	18	KATHLEEN C.M. CAMPBELL, ET AL., "D-Methionine Provides Protection Against Cisplatin Damage the Rat Stria Vascularis: A Semi-Quantitative Analysis," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 537, Pgs. 135	
	19	MICHAEL W. CHURCH, ET AL., "The Comparative Effects of Sodium Thiosulfate, Diethyldithiocarbamate, Fosfomycin and WR-2721 on Ameliorating Cisplatin-Induced Ototoxicity," <u>Hearing Research</u> , 1995, 86/1,2, Pgs. 195-203	
	20	PATRICIA M. DEEGAN, ET AL., "The nephrotoxicity, cytotoxicity and renal handling of a cisplatin-methionine complex in male Wistar rats," <u>Toxicology</u> , 1994, 89, Pgs. 1-14	
	21	PETER C. DEDON, ET AL., "Characterization of the Reactions of Platinum Antitumor Agents with Biologic and Nonbiologic Sulfur-Containing Nucleophiles," <u>Biochemical Pharmacology</u> , 1987, Vol. 36, No. 12, Pgs. 1955-1964.	
	22	MENDEL FRIEDMAN, ET AL., "The Utilization and Safety of Isomeric Sulfur-Containing Amino Acids in Mice," <u>J. Nutr.</u> , 1984, 114, Pgs. 2301-2310	
	23	RAMIN GABAIZADEH, ET AL., "Protection of Both Auditory Hair Cells and Auditory Neurons from Cisplatin Induced Damage," <u>Acta Otolaryngol</u> (Stockholm), 1997, 117, Pgs. 232-238.	
	24	DAVID R. GANDARA, ET AL., "Evaluation of Cisplatin Dose Intensity: Current Status and Future Prospects," <u>Anticancer Research</u> , 1989, 9, Pgs. 1121-1128	
	25	DAVID R. GANDARA, ET AL., "Cisplatin Chemoprotection and Rescue: Pharmacologic Modulation of Toxicity," <u>Seminars in Oncology</u> , February 1991, Vol. 18, No. 1, Suppl. 3, Pgs. 49-55	
	26	DONNA GLOVER, ET AL., "Clinical Trials of WR-2721 and Cis-Platinum," <u>I. J. Radiation Oncology, Biology, Physics</u> , May 1989, Vol. 16, No. 5, Pgs. 1201-1204	
	27	JORG HANNERMANN, ET AL., "Cisplatin-Induced Lipid Peroxidation and Decrease of Gluconeogenesis in Rat Kidney Cortex: Different Effects of Antioxidants and Radical Scavengers," <u>Toxicology</u> , 1988, 51, Pgs. 119-132	
	28	MARK M. JONES, ET AL., "Inhibition of cis-diamminedichloroplatinum (II)-induced renal toxicity in the rat," <u>Cancer Chemotherapy and Pharmacology</u> , 1986, 17, Pgs. 38-42	
	29	MARK M. JONES, ET AL., "Control of Nephrotoxicity in the Rat during Repeated cis-Platinum Treatments," <u>Journal of Applied Toxicology</u> , 1989, Vol. 9(4), Pgs. 229-233	

Examiner Signature		Date Considered	9/30/02
--------------------	---	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/911,195
				Filing Date	July 23, 2001
				Confirmation Number	2942
				First Named Inventor	Kathleen C.M. Campbell
				Group Art Unit	1614
Sheet	4	of	8	Attorney Docket No.	SIU 7396

2	30	MARK M. JONES, ET AL., "Thiol and Thioether Suppression of Cis-Platinum-Induced Nephrotoxicity in Rats Bearing the Walker 256 Carcinoma," <u>Anticancer Research</u> , 1989, 9: 1937-1942	
7	31	MARK M. JONES, ET AL., "Thioether Suppression of Cisplatin Nephrotoxicity in the Rat," <u>Anticancer Research</u> , 1991, 11, Pgs. 449-454	
9	32	MARK M. JONES, ET AL., "Coadministration of Dimethyl Sulfoxide Reduces Cisplatin Nephrotoxicity," <u>Anticancer Research</u> , 1991, 11, Pgs. 1939-1942	
9	33	MARK M. JONES, ET AL., "Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity," <u>Toxicology</u> , 1991, 68: Pgs. 227-247	
9	34	MARK M. JONES, ET AL., "Control of the Nephrotoxicity of Cisplatin by Clinically Used Sulfur-Containing Compounds," <u>Fundamental and Applied Toxicology</u> , 1992, 18, Pgs. 181-188	
9	35	CONSTANCE KIES, ET AL., "Comparative Value of L-, DL-, and D-Methionine Supplementation of an Oat-based Diet for Humans," <u>J. Nutr.</u> , 1975, 105, Pgs. 809-814	
9	36	RICHARD D. KOPKE, ET AL., "Use of Organotypic Cultures of Corti's Organ to Study the Protective Effects of Antioxidant Molecules on Cisplatin-Induced Damage of Auditory Hair Cells," <u>The American Journal of Otology</u> , 1997, 18, 559-571	
9	37	K. D. KORVER, ET AL., "Round window application of D-methionine provides cisplatin ototoxicity protection," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 536, Pg. 135	
9	38	JAN EGIL MELVIK, ET AL., "Reduction of cis-Dichlorodiammineplatinum-Induced Cell Inactivation by Methionine," <u>Inorganica Chimica Acta</u> , 1987, 137, Pgs. 115-118	
9	39	THOMAS J. MONTINE ET AL., "Role of Endogenous Sulfur-Containing Nucleophiles in an In Vitro Model of cis-Diamminedichloroplatinum(II)-Induced Nephrotoxicity," <u>Biochemical Pharmacology</u> , 1990, Vol. 39, No. 11, Pgs. 1751-1757	
9	40	SACHIKO NAKANO, ET AL., "Potentiation of Cisplatin-Induced Lipid Peroxidation in Kidney Cortical Slices by Glutathione Depletion," <u>Japan. J. Pharmacol.</u> , (1989), 50, Pgs. 87-92	
9	41	T. ORMOND, ET AL., "Reduced Nephrotoxicity <u>In Vivo</u> and <u>In Vitro</u> of Cisplatin-Methionine Complex," <u>Brit. J. Pharmacol. (suppl.)</u> , (1988), 95, Pg. 584P	

Examiner Signature		Date Considered	9/30/02
--------------------	---	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/911,195
				Filing Date	July 23, 2001
				Confirmation Number	2942
				First Named Inventor	Kathleen C.M. Campbell
				Group Art Unit	1614
Sheet	5	of	8	Attorney Docket No.	SIU 7396

9	42	KENNETH J. PRINTEN, ET AL., "Utilization of D-methionine during total parenteral nutrition in postsurgical patients," <u>The American Journal of Clinical Nutrition</u> , June 1979, 32, Pgs. 1200-1205	
9	43	RADHIKA P. RAVI, ET AL., "Relationship of Pharmacodynamic Effects of Cisplatin to the Glutathione Levels in Cochlea, Inferior Colliculus and Kidney," <u>Pharmacologist</u> , 1991, 33(3), D-19, 402, P. 217	
9	44	RADHIKA RAVI, ET AL., "Diethyldithiocarbamate Protects Against Cisplatin Ototoxicity and Nephrotoxicity," <u>Otolaryngology Head and Neck Surgery</u> , 1992, 107(2), Poster 5, P. 232	
8	45	D. H. RESER, ET AL., "Physiological evidence for protection from cis-platin ototoxicity by D- and L-methionine in vivo," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 203, P. 51	
2	46	M. B. RHO ET AL., "Structural evidence for protection from cisplatin ototoxicity by both D- and L-methionine in vivo," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 202, P. 51	
1	47	P. S. SCHEIN, "Ethyol™ (WR-2721): a chemoprotective agent for platinum anti-cancer drugs," <u>Speaker Abstracts</u> (XP-002053095) <i>no date</i>	
9	48	VANESSA GAYL SCHWEITZER, "Cisplatin-Induced Ototoxicity: The Effect of Pigmentation and Inhibitory Agents," <u>Laryngoscope</u> , April 1993, 103, Pgs. 1-52	
2	49	SHA, ET AL., "Antioxidant therapy attenuates gentamicin-induced ototoxicity," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 535, P. 134	
9	50	SERGIO TOGNELLA, "Pharmacological interventions to reduce platinum-induced toxicity," <u>Cancer Treatment Reviews</u> , 1990, 17, Pgs. 139-142	
9	51	MARCO TRESKES, ET AL., "WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach," <u>Cancer Chemotherapy and Pharmacology</u> , 1993, 33, Pgs. 93-106	
9	52	T. VAN DE WATER, ET AL., "Oxidative stress in the inner ear: Combinatorial therapy;" (202) M. B. Rho et al., "Structural evidence for protection from cisplatin ototoxicity by both D- and L-methionine in vivo," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 6, P. 2	

Examiner Signature		Date Considered	9/30/02
--------------------	---	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/911,195
				Filing Date	July 23, 2001
				Confirmation Number	2942
				First Named Inventor	Kathleen C.M. Campbell
				Group Art Unit	1614
Sheet	6	of	8	Attorney Docket No.	SIU 7396

Q	53	ERNEST M. WALKER, JR. ET AL., "Methods of Reduction of Cisplatin Nephrotoxicity," <u>Annals of Clinical and Laboratory Science</u> , 1981, Vol. 11, No. 5, Pgs. 397-409	
g	54	C. A. WHITWORTH ET AL., "Alpha-lipoic acid as a protective agent against ototoxicity;" (535) S. H. Sha et al., "Antioxidant therapy attenuates gentamicin-induced ototoxicity," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 532, P. 134	
g	55	ALLISON YATES ZEULKA ET AL., "Nitrogen Retention in Men Fed Isolated Soybean Protein Supplemented with L-Methionine, D-Methionine, N-Acetyl-L-Methionine, or Inorganic Sulfate," <u>J. Nutr.</u> , 1976, 106, Pgs. 1286-1291	
g	56	BURCHENAL, J. H., ET AL., "Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives," <u>Biochimie</u> , 1978, 60, Pgs. 961-965	
g	57	DREWINKO, B., ET AL., "The Effect of <i>cis</i> -Diamminedichloroplatinum(II) on Cultured Human Lymphoma Cells and Its Therapeutic Implications," <u>Cancer Research</u> , December 1973, 33, Pgs. 3091-3095	
g	58	DROBNIK, JAROSLAV, ET AL., "Inactivation Of Bacteriophages With <i>Cis</i> -Platinum(II) Diamminedichloride," <u>Chem.-Biol. Interactions</u> , 1975, Pgs. 365-375	
g	59	FRIEDMAN, M. E., ET AL., "The Blocking Of The Tetrachloroplatinate(II) Inhibition Of Malate Dehydrogenase By Sulfur-Containing Amino Acids," <u>Biochimica et Biophysica Acta</u> , 1974, 341, Pgs. 277-283	
g	60	HAYES, D., ET AL., "Amelioration Of Renal Toxicity Of High Dose <i>Cis</i> -Platinum Diammine Dichloride (CPDD) By Mannitol Induced Diuresis," <u>Proc. Am. Assoc. Cancer Res.</u> , 1976	
g	61	MERRIN, CLAUDE, "A New Method To Prevent Toxicity With High Doses Of <i>Cis</i> Diammine Platinum (Therapeutic Efficacy In Previously Treated Widespread And Recurrent Testicular Tumors)," <u>Proc. Am. Assoc. Cancer Res.</u> , 1976	
g	62	SPEER, R. J., ET AL., "Coordination Complexes of Platinum as Antitumor Agents," <u>Cancer Chemotherapy Reports</u> , 1975, Part I, Vol. 59, No. 3, Pgs. 629-641	
Q	63	WARD, J. M., ET AL., "Modification of the Renal Toxicity of <i>cis</i> -Dichlorodiammineplatinum(II) With Furosemide in Male F344 Rats," <u>Cancer Treatment Reports</u> , 1977, Vol. 61, No. 3, Pgs. 375-379	

Examiner Signature		Date Considered	9/30/02
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/911,195
				Filing Date	July 23, 2001
				Confirmation Number	2942
				First Named Inventor	Kathleen C.M. Campbell
				Group Art Unit	1614
Sheet	7	of	8	Attorney Docket No.	SIU 7396

64	CARDINI, G., ET AL., "La Radioprotezione Dei Cromosomi Delle Cellule Midollari Umane In Vitro," <u>Radiobiologia Radioterapia E Fisica Medica</u> , 1967, Vol. 22, No. 6, Pgs. 371-375
65	CARRITHERS, S. L., ET AL., "Methylation Of Radiation Protector Compounds By Thiol Methyltransferase," <u>FASEB</u> , 1991, Vol. 5, No. 4, Pg. A824
66	CORREA, J. N., ET AL., "Radiosensitization and radioprotection on murine chondrosarcoma," <u>Radiation Research</u> , 1978, Vol. 74, No. 3, Pg. 517
67	DE VECCHI, A., "Sperimentazione Clinica Di Una Nuova Sostanza Radioprotettiva (Cloruro Di Metil-Metionin-Sulfonio)," <u>Radiobiologia Radioterapia E Fisica Medica</u> , 1967, Vol. 22, No. 5, Pgs. 355-370
68	GESSLER, N., ET AL., "Antiradiation effects of S-methylmethionine (Vitamin U)," <u>Prikl. Biokhim. Mikrobiol.</u> , 1996, Vol. 32, No. 6, Pgs. 666-668
69	INFANTE, G. A., ET AL., "Chemical radioprotection on biological important compounds," <u>Radiation Research</u> , 1976, Vol. 67, No. 3, Pg. 637
70	KIDO, K., "The influence of methylmethionine sulfonium chloride (MMSC) on survivors of mice after X-ray irradiation, especially the consideration of the drug effect for the degeneration of intestinal mucosa," <u>Kansai Ika Daigaku Zasshi</u> , 1973, Vol. 25, No. 1, Pgs. 104-107
71	KOVACS, V., ET AL., "Study of the Radiation Protection Effect of Selenium-Methionine by Determining the Paramagnetic Properties of Liver Tissues of Mice," 1988, <u>Acta Physica Hungarica</u> , Vol. 64, No. 1-3, Pgs. 321-326
72	MEKHTIEV, M. A., ET AL., "Radioprotective effect during the separate and combined use of DL-methionine and thyroxine," <u>Database Chemabs Chemical Abstracts Service</u> , Abstract No. 76:54431, 1970 (see also <u>Tr. Inst. Fiziol., Akad. Nauk Azerb. SSR</u> , Vol. 11, pp. 83-100, 1970)
73	MOLTENI, F., ET AL., "The use of S-adenosyl-methionine as a radioprotective agent," <u>Gazzetta Medica Italiana</u> , 1978, Vol. 137, No. 7-8, Pgs 303-308
74	SALIKHODZHAEV, Z., ET AL., "Stimulation of postirradiation recovery of rat haemopoiesis by a cobalt preparation," <u>Database Biosis Biosciences Information Service</u> , Philadelphia, Pennsylvania, Abstract No. 08095385 (see also <u>Radiobiologia</u> , Vol. 31, No. 6, pp. 835-837, 1991)
75	ROMITO, S., "Sulla radioprotezione cromosomica in vitro: esperienze con metionina, acido aspartico, leucina, lisina," <u>Fracastoro</u> , 1969, Vol. 62, No. 6, Pgs. 576-581


Examiner Signature		Date Considered	5/30/02
--------------------	---	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/911,195
				Filing Date	July 23, 2001
				Confirmation Number	2942
				First Named Inventor	Kathleen C.M. Campbell
				Group Art Unit	1614
Sheet	8	of	8	Attorney Docket No.	SIU 7396


	76	SRINIVASAN, V., ET AL., "Radioprotection By Misoprostol (PGE ₁ Methyl Analog) In Combination With Vitamin E, Selenomethionine and WR-3689794," <u>Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2</u> , edited by K. V. Honn et al., 1997, Plenum Press, New York, Pgs. 791-797	
---	----	---	--

Examiner Signature		Date Considered	9/30/02
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Express Mail Label
No. EV504795968US

SIU 7396
PATENT

118105

1614/\$
DFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Kathleen C.M. Campbell
Serial No. 09/911,195
Filed July 23, 2001
Confirmation No. 2942
For THERAPEUTIC USE OF D-METHIONINE TO
REDUCE THE TOXICITY OF NOISE
Examiner Rebecca Cook

Art Unit 1614

January 14, 2005

AMENDMENT C

TO THE COMMISSIONER FOR PATENTS,
SIR:

In response to the Office action mailed on August 23, 2004, please enter the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/arguments begin on page 9 of this paper.

Conclusion begins on page 19 of this paper.

01/24/2005 HNGUYEN1 00000072 09911195

01 FC:2252

225.00 OP

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. - 19. (cancelled).

20. (original). A method for preventing or treating ototoxicity in a patient exposed to noise for a time and at an intensity sufficient to result in ototoxicity, comprising administering to said patient an anti-ototoxic effective amount of an otoprotective agent comprising methionine.

21. (currently amended). **The** **[[A]]** method as set forth in claim 20 wherein said otoprotective agent is selected from the group consisting of D-methionine, L-methionine, D,L-methionine, a pharmaceutically acceptable salt thereof and a combination thereof.

22. (currently amended). **The** **[[A]]** method as set forth in claim 21, wherein said otoprotective agent is D-methionine.

23. (currently amended). **The** **[[A]]** method as set forth in claim 21, wherein said otoprotective agent is L-methionine.

24. (currently amended). **The** **[[A]]** method as set forth in claim 20, wherein said otoprotective agent is administered prior to said noise exposure.

25. (currently amended). **The** **[[A]]** method as set forth in claim 20, wherein said otoprotective agent is administered simultaneously with said noise exposure.

26. (currently amended). **The [[A]]** method as set forth in claim 20, wherein said otoprotective agent is administered subsequently to said noise exposure.

27. (currently amended). **The [[A]]** method as set forth in claim 20, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 336 hours before to about 336 hours after said exposure to noise.

28. (currently amended). **The [[A]]** method as set forth in claim 27, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 48 hours before to about 48 hours after said exposure to noise.

29. (currently amended). **The [[A]]** method as set forth in claim 20, wherein said otoprotective agent is administered orally, parenterally, or topically to the round window membrane.

30. - 31. (cancelled).

32. (currently amended). **The [[A]]** method as set forth in claim 29, wherein the administration of said effective amount of said otoprotective agent results in a blood serum level equivalent to that achieved by parenteral administration in the range of from about 10 mg/kg body weight to about 400 mg/kg body weight.

33. (currently amended). **The [[A]]** method as set forth in claim 20, further comprising administering to said patient a supplemental amount of said otoprotective agent after the administration of said effective amount.

34. (currently amended). The **[[A]]** method as set forth in claim 33, wherein said supplemental amount of said otoprotective agent is administered orally, parenterally, or topically to the round window membrane of said patient.

35. (currently amended). The **[[A]]** method as set forth in claim 34, wherein the administration of said supplemental amount of said otoprotective agent is sufficient to maintain an effective blood serum level of the otoprotective agent in said patient for a period of from one to fourteen days after the administration of said effective amount.

36. (currently amended). The **[[A]]** method as set forth in claim 34, wherein the administration of said supplemental amount of said otoprotective agent is sufficient to maintain a blood serum level of otoprotective agent within said patient of at least about 10% of the blood serum level achieved by administration of the effective amount of said otoprotective agent.

37. (currently amended). The **[[A]]** method as set forth in claim 34, wherein the administration of said supplemental amount of said otoprotective agent is sufficient to maintain a blood serum level of otoprotective agent within said patient of from about 20% to about 70% of the blood serum level achieved by administration of the effective amount of said otoprotective agent.

38. (original). A method for preventing or treating ototoxicity in a patient exposed to noise for a time and at an intensity sufficient to result in ototoxicity, the method comprising administering to said patient an effective amount of an otoprotective agent comprising D-methionine, L-methionine, D,L-methionine, a combination thereof or a pharmaceutically acceptable salt thereof, the administration of said effective amount of said otoprotective agent resulting in a blood serum level equivalent to that achieved by parenteral administration in the range of from about 10 mg/kg body weight to about 400 mg/kg body weight.

39. (currently amended). The **[[A]]** method as set forth in claim 38, wherein said otoprotective agent is administered parenterally, orally or topically to the round window membrane of said patient.

40. (currently amended). The **[[A]]** method as set forth in claim 38, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 336 hours before to about 336 hours after said exposure to noise.

41. (currently amended). The **[[A]]** method as set forth in claim 38, further comprising administering to said patient a supplemental amount of said otoprotective agent after the administration of said effective amount, the administration of said supplemental amount of said otoprotective agent being sufficient to maintain a blood serum level of otoprotective agent within said patient of from about 20% to about 70% of the blood serum level achieved by administration of the effective amount of said otoprotective agent.

42. - 56. (cancelled).

57. (currently amended). A method for preventing or treating ototoxicity in a patient exposed to noise for a time and at an intensity sufficient to result in ototoxicity, comprising administering to said patient an anti-ototoxic effective amount of an otoprotective agent comprising methionine; provided that, at the time said otoprotective agent is administered, an antineoplastic effective dose of cisplatin has not been **administered or** prescribed for administration to said patient.

58. (currently amended). The **[[A]]** method as set forth in claim **57** **[[60]]** wherein said otoprotective agent is selected from the group consisting of D-methionine,

L-methionine, D,L-methionine, a pharmaceutically acceptable salt thereof and a combination thereof.

59. (currently amended). **The [[A]]** method as set forth in claim 57, wherein said otoprotective agent is D-methionine.

60. (currently amended). **The [[A]]** method as set forth in claim 57, wherein said otoprotective agent is administered prior to said noise exposure.

61. (currently amended). **The [[A]]** method as set forth in claim 57, wherein said otoprotective agent is administered simultaneously with said noise exposure.

62. (currently amended). **The [[A]]** method as set forth in claim 57, wherein said otoprotective agent is administered subsequently to said noise exposure.

63. (currently amended). **The [[A]]** method as set forth in claim 57, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 336 hours before to about 336 hours after said exposure to noise.

64. (currently amended). **The [[A]]** method as set forth in claim 63, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 48 hours before to about 48 hours after said exposure to noise.

65. (currently amended). **The [[A]]** method as set forth in claim 60, wherein said otoprotective agent is administered orally, parenterally, or topically to the round window membrane.

66. (currently amended). **The [[A]]** method as set forth in claim 65, wherein the administration of said effective amount of said otoprotective agent results in a blood serum level equivalent to that achieved by parenteral administration in the range of from about 10 mg/kg body weight to about 400 mg/kg body weight.

67. (currently amended). **The [[A]]** method as set forth in claim 57, further comprising administering to said patient a supplemental amount of said otoprotective agent after the administration of said effective amount.

68. (currently amended). **The [[A]]** method as set forth in claim 67, wherein said supplemental amount of said otoprotective agent is administered orally, parenterally, or topically to the round window membrane of said patient.

69. (currently amended). **The [[A]]** method as set forth in claim 68, wherein the administration of said supplemental amount of said otoprotective agent is sufficient to maintain an effective blood serum level of the otoprotective agent in said patient for a period of from one to fourteen days after the administration of said effective amount.

70. (currently amended). **The [[A]]** method as set forth in claim 68, wherein the administration of said supplemental amount of said otoprotective agent is sufficient to maintain a blood serum level of otoprotective agent within said patient of from about 20% to about 70% of the blood serum level achieved by administration of the effective amount of said otoprotective agent.

71. (currently amended). A method for preventing or treating ototoxicity in a patient exposed to noise for a time and at an intensity sufficient to result in ototoxicity, the method comprising administering to said patient an effective amount of an otoprotective agent comprising D-methionine, L-methionine, D,L-methionine, a combination thereof or a pharmaceutically acceptable salt thereof, the administration of

said effective amount of said otoprotective agent resulting in a blood serum level equivalent to that achieved by parenteral administration in the range of from about 10 mg/kg body weight to about 400 mg/kg body weight, provided that, at the time said otoprotective agent is administered, an antineoplastic effective dose of cisplatin has not been **administered or** prescribed for administration to said patient.

72. (currently amended). **The [[A]]** method as set forth in claim 71, wherein said otoprotective agent is administered parenterally, orally or topically to the round window membrane of said patient.

73. (currently amended). **The [[A]]** method as set forth in claim 71, wherein said effective amount of said otoprotective agent is administered to said patient in a time period ranging from about 336 hours before to about 336 hours after said exposure to noise.

74. (currently amended). **The [[A]]** method as set forth in claim 71, further comprising administering to said patient a supplemental amount of said otoprotective agent after the administration of said effective amount, the administration of said supplemental amount of said otoprotective agent being sufficient to maintain a blood serum level of otoprotective agent within said patient of from about 20% to about 70% of the blood serum level achieved by administration of the effective amount of said otoprotective agent.

REMARKS

Claims 1-19, 30-31 and 42-56 are cancelled; these claims are cancelled to expedite prosecution and applicant reserves the right to present these claims in a continuation application. Claims 20-29, 32-41 and 57-74 are pending. Upon entry of this amendment, claims 21-29, 32-37, 39-42 and 57-74 are amended.

I. Priority

The Examiner asserts that the parent applications do not support the instant method of use.¹ Applicant respectfully submits that the methods of use are supported by at least one parent application. Generally, the claimed methods of use are directed to preventing or treating ototoxicity in a patient exposed to noise for a time and at an intensity sufficient to result in ototoxicity by administration of an otoprotective agent comprising methionine. U.S. Application Serial No. 09/057,065 (now U.S. Patent No. 6,265,386) was filed on April 8, 1998 and the specification supports the claimed methods of use. For example, the specification discloses "the present invention provides a method for preventing or reducing ototoxicity in a patient exposed to noise for a time and at an intensity sufficient to result in ototoxicity, comprising administering to the patient an anti-ototoxic effective amount of a methionine protective agent."² There are similar passages throughout the specification as well as a section describing noise-induced hearing loss in the specification.³ After the description of methionine protective agents of the invention, the specification discloses "these methionine protective agents can be employed ... in methods for treating human and animal patients exposed to ototoxic noise levels...."⁴ Accordingly, the claimed methods of use

¹See Office action dated August 23, 2004 at page 2.

²Column 5, lines 63-67 of U.S. Patent No. 6,265,386.

³Column 17, line 45 - column 18, line 4 of U.S. Patent No. 6,265,386.

⁴See page , column 18, line 62 - column 19, line 2 of U.S. Patent No. 6,265,386.

are supported by the specification of U.S. Application Serial No. 09/057,065 and thus, have a priority date of April 8, 1998.

II. Campbell Declaration

The Examiner states that the Declaration of June 15, 2004 by Dr. Campbell would not be persuasive, even if signed, because it is opinion only. Applicant respectfully requests reconsideration of the Campbell declaration simultaneously submitted herewith, as it is signed and contains underlying facts, which are probative. The Campbell declaration has been modified and amplified since the version dated June 15, 2004 was submitted. Although opinion on the ultimate legal conclusion is not probative, a persuasively supported statement by a person skilled in the art about what was not obvious is probative.⁵ In this case, Dr. Campbell has stated that her invention was not obvious from the Campbell et al. reference based on her knowledge of the art combined with reasonable inferences a person skilled in the art would have made upon review of the reference. The statements directed to the knowledge of a person skilled in the art and reasonable inferences derived from the reference support her conclusion that her invention as defined by the subject claims was not obvious, and thus, her signed declaration must be regarded as probative. It is respectfully submitted that, in reaching an ultimate evaluation of obviousness *vel non*, the Examiner must give proper weight both to the opinions expressed by Dr. Campbell and the factual analysis by which those opinions are supported.

III. 35 U.S.C. § 112 Rejections

Reconsideration is respectfully requested of the rejection of claims 3-4, 15, 21-29 and 32-74 under 35 U.S.C. § 112, second paragraph, as indefinite.

Claims 1, 3-4, 15, and 42-56 are cancelled, thus the rejection is moot with respect to these claims.

⁵See In re Lindell, 385 F.2d 453 (CCPA 1965).

Claims 57 and 71 are amended to state “provided that, at the same time said otoprotective agent is administered, an antineoplastic effective dose of cisplatin has not been administered or prescribed for administration to said patient.” The words “administered or” were added to make it clear that the patient has not received and is not receiving cisplatin.

Claims 21-29, 32-37, 39-41, 58-70 and 72-74 are amended as suggested to make their dependent status clear. In view of these amendments, it is respectfully requested that the rejections under 35 U.S.C. § 112 be withdrawn.

IV. 35 U.S.C. § 102 and § 103 Rejections over Campbell et al.

Applicant respectfully submits that Campbell et al., Hearing Research 102 (1996) 90-98, does not inherently anticipate claims 20-29 and 32-41. Campbell et al. disclose the treatment of five groups of rats. These groups were an untreated control, a treated control (16 mg/kg cisplatin), and three treated experimental groups ((1) 75 mg/kg D-methionine + 16 mg/kg cisplatin; (2) 150 mg/kg D-methionine + 16 mg/kg cisplatin; and (3) 300 mg/kg D-methionine + 16 mg/kg cisplatin). Campbell et al. do not address any other cause of ototoxicity except that from cisplatin. In addition, D-methionine was not used to treat human patients; rats were the experimental subjects.

The Office has asserted that there would inherently be a subset of those patients exposed to cisplatin as described in Campbell et al., that were also exposed to ototoxicity-inducing noise. However, inherency may not be established if there is only a probability or possibility that a certain result may occur.⁶ There is no disclosure by Campbell et al. that shows that any of the rats in any of the five groups were exposed to a level of noise that would cause ototoxicity. Even if it were possible that a subset of the rats were also exposed to an ototoxic level of noise, there is nothing in the disclosure in Campbell et al. from which it can be shown that such exposure inevitably did occur. Moreover, the Campbell declaration states that the rats were in a controlled environment during testing and purposefully not exposed to an ototoxic level of noise.

⁶*In re Oelrich*, 666 F.2d 578.

Accordingly, Campbell et al. do not disclose any facts which would support even a possibility that any subset of rats were actually exposed to both an ototoxic level of cisplatin and an ototoxic level of noise. Because the Campbell declaration affirmatively states that care was taken to avoid exposing the rats tested to an ototoxic level of noise, there is essentially zero likelihood that they were so exposed. Thus, claims 20-29 and 32-41 are not anticipated by Campbell et al.

Because Campbell does not teach the administration of methionine or any other compound for treatment of noise-induced ototoxicity and contains no inherent disclosure of such treatment, either incidental to treatment of cisplatin-induced hearing loss or otherwise, there is no basis for the §103 rejection of claims 20-29 and 32-41 over Campbell. The Examiner's conclusion that it would have been obvious to treat noise-induced ototoxicity with L-methionine is based on the premise that Campbell inherently treats noise-induced hearing loss with D-methionine. But the premise is erroneous. As there is no basis remaining for the §103 rejection over Campbell, it is respectfully requested that this ground of rejection be withdrawn.

V. 35 U.S.C. § 102 and § 103 Rejections over Kopke et al.

As detailed above, the priority date of the subject claims is April 8, 1998, so only the Kopke provisional application (U.S. application serial no. 60/069,761) filed on December 16, 1997 is prior to the priority date of the subject claims. Accordingly, only the disclosure of the Kopke provisional is discussed.

A. Novelty

Claims 20-29, 32-41 and 57-74 are directed to methods for preventing or treating ototoxicity in a patient exposed to noise by administering an effective amount of an otoprotective agent comprising methionine. It is respectfully submitted that Kopke contains no specific teaching of the administration of methionine for treatment of hearing loss, and particularly fails to teach or suggest the unique advantages of methionine for such purpose. In this connection, it should be recognized that Kopke's

provisional disclosure is not limited to treatment of noise-induced hearing loss, but instead relates to hearing loss from a variety of disparate insults including aminoglycoside antibiotics, chemotherapeutic agents, noise, and closed head injuries. Kopke discloses that applying R-N6-phenylisopropyl adenosine (R-PIA) to the round window membrane of the inner ear or systemically is effective to combat hearing loss by upregulating the activity of γ -glutamyl cysteine synthase for intracellular synthesis of glutathione. Kopke further discloses the optional administration of a sulfur compound to serve as substrate for glutathione synthesis. Methionine is mentioned along with a number of other sulfur compounds, prominently oxothiazolidine-4-carboxylic acid (OTC), that can be transported into an inner ear hair cell and serve as a substrate for glutathione synthesis.

However, Kopke does not suggest that methionine is specific for treatment of noise-induced hearing loss, as opposed to hearing loss resulting from chemotherapeutic agents, aminoglycoside antibiotics, or closed head injuries. Moreover, there is no emphasis in the Kopke reference on the administration of any particular sulfur compound other than OTC; and the principal teaching is the administration of R-PIA for upregulating antioxidant enzymes such as γ -glutamyl cysteine synthase, and upregulating adenosine in neural tissue to decrease the release of potentially damaging excitotoxic amino acids such as glutamate and thereby limit NO damage.

With respect to the specific problem of noise-induced hearing loss, nothing in Kopke would lead a person skilled in the art to select methionine over other compounds that could be transported into an inner ear hair cell and synthesized into glutathione or to select methionine over the other compounds disclosed (e.g., L-2-oxothiazolidine-4-carboxylic acid (OTC), L-N-acetylcysteine (L-NAC), S-adenosyl-L-methionine (SAME)). Moreover, Kopke et al. effectively teach away from selection of methionine. For example, Kopke et al. primarily discuss OTC (also called procysteine) as the compound that can be transported into an inner ear hair cell and synthesized into glutathione. In addition, the examples (Figures 1 and 2) disclose use of the adenosine agonist, R-PIA,

by itself as a compound which reduces hearing loss from a noise insult. Accordingly, in the specific case of noise-induced hearing loss, Kopke et al. would not have led a person skilled in the art to select methionine from the possible compounds that can be transported into an inner ear hair cell and synthesized into glutathione, and thus, the subject claims are not anticipated by the Kopke provisional application.

B. Nonobviousness

Claims 20-29, 32-41 and 57-74 would not have been rendered obvious by the Kopke provisional application. Since the reference treats the administration of a sulfur compound as merely optional, and contains no guidance for the selection of any specific sulfur compound to promote glutathione synthesis in the treatment of noise-induced hearing loss, it is respectfully submitted that the claimed method calling for the administration of methionine is not rendered *prima facie* obvious by Kopke. Moreover, *prima facie* obviousness must be evaluated against the entire background of the art, not just against an isolated reference which can be selected by searching with the inventor's claims at hand.⁷ As detailed in the accompanying declaration of Dr. Campbell, it is known that the mechanisms causing hearing loss differ markedly among the various insults from which hearing loss results, that the effectiveness against any particular cause of hearing loss varies among sulfur compounds, and that the effectiveness of any particular sulfur compound typically varies among the causes of hearing loss. Thus, absent more specific teaching by Kopke, one skilled in the art would not have been led to expect that all of the sulfur compounds listed would be effective against all sources of hearing loss, or that methionine in particular would be effective against hearing loss as arising specifically from exposure to noise.

Even if *prima facie* obviousness could otherwise be established, it is respectfully submitted that any such finding should be overcome by the empirical evidence presented in the attached Campbell declaration. The data presented and described by Dr. Campbell demonstrate that D-methionine alone, without the co-administration of R-

⁷*In re Kuderna*, 165 U.S.P.Q. 575 (C.C.P.A. 1970).

PIA, has a decidedly beneficial effect against noise-induced hearing loss. As further explained in the declaration, this beneficial effect is believed to result, at least in part, from the function of methionine as an antioxidant, and not merely as a substrate for the γ -glutamyl cysteine synthase catalyzed intracellular synthesis of glutathione as described by Kopke. For example, attached data show the ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG) is increased by administration of D-methionine. The effect of D-methionine on the GSH/GSSG ratio may be more important than the absolute glutathione concentration to protection of a subject from noise-induced hearing loss. Even for glutathione synthesis, Kopke emphasizes the importance of upregulating the synthase by administration of an adenosine agonist such as R-PIA, apparently to accelerate the rate of glutathione formation and/or to increase glutathione to supranormal levels. Applicant has found that methionine is effective without the necessity of administering an adenosine agonist. The striking result achieved by D-methionine, which is not predicted by Kopke or other references known to applicant, constitutes substantial secondary evidence overcoming any *prima facie* obviousness which the Kopke disclosure might otherwise be deemed to create.⁸

It is recognized that the data presented in the Campbell declaration relate specifically only to D-methionine. However, as Dr. Campbell testifies, it is now reasonable to expect that they should at least establish useful efficacy for the racemic mixture which includes 50% of the D-isomer. Although the efficacy of the L-isomer has not been demonstrated empirically, it is Dr. Campbell's further expectation that it will also be effective, irrespective of the presence or absence of an adenosine agonist such as R-PIA, especially in view of the apparent ability of methionine to be reversibly oxidized and to function as a direct free radical scavenger. See Campbell declaration,

⁸ Where present, secondary evidence must be considered in evaluating obviousness; *Demaco Corporation v. F. von Langsdorff Licensing Limited*, 851 F.2d 1387, 7 USPQ2d 1222 (Fed. Cir. 1988). "Indeed, evidence of secondary considerations may often be the most probative and cogent evidence in the record;" *Stratoflex v. Aeroquip*, 713 F.2d 1530, 1538-1539, 218 USPQ 871 (Fed. Cir. 1983)

paragraph 20.⁹ Thus, it is respectfully submitted that any basis for *prima facie* obviousness has been overcome, and that claims 20-29, 32-41 and 57-74 should be deemed patentable over Kopke under 35 U.S.C. §103.

When weighing rebuttal evidence, the Office should avoid giving it no weight.¹⁰ The specific and strikingly beneficial effect of methionine against noise-induced ototoxicity would not have been obvious from a reference which attempts to deal with multiple causes of hearing loss, and which indiscriminately lists methionine with a number of other sulfur compounds without describing which of these compounds would be effective which causes of ototoxicity. The determination of patentability should be made on the entire record where the facts of rebuttal are considered along with the facts establishing the *prima facie* case of obviousness. Stated another way, competent rebuttal evidence requires the Office to start the nonobviousness analysis again by evaluating all the evidence—facts supporting and facts rebutting the *prima facie* case—and determining whether, on the whole record, the invention is nonobvious.¹¹

In a series of studies undertaken, D-methionine was tested for protection and rescue of animals exposed to noise. These studies were conducted at the direction of applicant, Dr. Campbell, and the results are presented in the Campbell declaration. The results show that D-methionine administration to the animals significantly decreased the threshold shift, significantly decreased the outer hair cell (OHC) and inner hair cell (IHC) loss and significantly increased the ratio of reduced glutathione (GSH) to oxidized glutathione (GSSG) in the cochlea as compared with the control animals. Additionally, although the number of animals tested for the rescue effect of D-methionine was not sufficient for a rigorous statistical analysis, the trend in the ABR

⁹ If the Examiner deems it necessary, applicant is prepared to obtain and provide data on the efficacy of L-methionine vs. noise-induced hearing loss. However, Kopke discloses only "methionine" without specific connection to noise induced hearing loss; so it is believed that the noise data for D-Met should suffice for patentability of claim 20. At all events, the data submitted should be sufficient to support patentability of claims 22 and 59 which specifically require D-methionine.

¹⁰See MPEP 2144.08.

¹¹See MPEP 706.01.

threshold data 21 days after noise exposure showed a smaller threshold change in the D-methionine treated groups as compared to the treated control group. Thus, the data presented in the Campbell declaration were striking in view of the Kopke et al. disclosure emphasizing the importance of an agent (e.g., R-PIA) which upregulates an antioxidant enzyme activity for treating the effect of various insults on hearing.

Furthermore, Kopke et al. do not enable a person of ordinary skill to use the whole range of compounds for all ototoxic insults as disclosed. This deficiency is apparent from the variation in causative mechanisms of hearing loss, differences in efficacy among various sulfur compounds in treating hearing loss, and differences in therapeutic mechanisms of different sulfur compounds, all as alluded to above, detailed in the Campbell declaration, and discussed generally hereinbelow. If the Kopke article is read in light of these real world considerations, it cannot be construed as teaching that each of the listed sulfur compounds is effective against hearing loss caused by each of the listed insults; or, if the Kopke reference is so construed, it must be deemed non-enabling. For example, one skilled in the art should not interpret Kopke et al. as categorically teaching that all compounds that can be transported into an inner ear hair cell and synthesized into glutathione are effective against hearing loss due to administration of aminoglycoside antibiotics, chemotherapeutic agents, noise exposure and closed head injuries. For in the Campbell declaration, Dr. Campbell presents evidence that it is uncertain whether all compounds that can be transported into an inner ear hair cell and synthesized into glutathione are effective against hearing loss arising from each of the disclosed insults because mechanisms of hearing loss differ among insults, therapeutic mechanisms differ among insults, and the effectiveness of similar compounds for a given insult differs greatly.

Moreover, as described in more detail in the Campbell declaration, the morphology, physiology and biochemistry of the cells of the ear differ among causes. For example, noise causes temporary vasoconstriction in the auditory system and noise-induced hearing loss may be secondary to reperfusion injury. In addition, noise can induce microlesions in cochlear hair cell plasma membranes, breaks in the reticular

lamina, and glutamate excitotoxicity at the synapse of the spiral ganglion. Furthermore, noise exposure induces expression of heat shock proteins in the cochlea and changes cochlear gene expression. In contrast, cisplatin does not induce the above cell changes. Cisplatin can damage cells by causing DNA intra- and interstrand cross links preventing cell replication and by binding to the L-methionine in protein and disrupting the protein and damaging or killing cells. Additionally, cisplatin may soften the cuticular plate and cause more lysosomal bodies to be present in the OHC's apical portion. Furthermore, cisplatin can cause stria changes of cystic degeneration and protrusions into the endolymphatic duct prior to cell death.

Additionally, although there may be some common therapeutic mechanisms for plural causes, many therapeutic mechanisms differ among causes. Increasing the glutathione concentration and free radical concentration may be a common therapeutic mechanism to hearing loss from many insults, but these mechanisms are common to myriad disease states. D-methionine, for example, can bind to the platinum metal center of cisplatin, and as such, may displace protein-bound L-methionine from the platinum center. This binding property could be one mechanism through which D-methionine acts as an otoprotective agent for cisplatin administration. However, this mechanism cannot be one that is important for noise-induced ototoxicity as there is no specific toxic agent for D-methionine to interact with. Thus, the therapeutic mechanisms for noise-induced and cisplatin-induced hearing loss are different.

Furthermore, the effectiveness of similar compounds for a given insult differs greatly. For example, Jones et al. report that methionine and related compounds are the most effective agents against nephrotoxicity associated with CDDP administration as compared to a number of other agents tested, many of which are sulfur-containing nucleophiles.¹² In addition, unlike some other sulfur compounds and other amino acids, methionine can be reversibly oxidized and can act as a direct free radical scavenger. This oxidative behavior may be one property that makes methionine an advantageous anti-ototoxicity agent.


¹²Jones, M.M; Basinger, M.A. *Anticancer Res.* **1989**, 9, 1937.

CONCLUSION

Applicant submits that the present application is now in a condition for allowance and requests early allowance of the pending claims.

A check in the amount of \$225.00 for a two month extension of time. The Commissioner is hereby authorized to charge any underpayment and credit any overpayment of government fees to Deposit Account No. 19-1345.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "John K. Roedel, Jr.", written in dark ink.

John K. Roedel, Jr., Reg. No. 25,914
SENNIGER, POWERS
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

JKR/JSH/dep

Claim		Date	
Final	Original		
	1	2/2/70	
	2	2/2/70	
	3	2/2/70	
	4	2/2/70	
	5	2/2/70	
	6	2/2/70	
	7	2/2/70	
	8	2/2/70	
	9	2/2/70	
	10	2/2/70	
	11	2/2/70	
	12	2/2/70	
	13	2/2/70	
	14	2/2/70	
	15	2/2/70	
	16	2/2/70	
	17	2/2/70	
	18	2/2/70	
	19	2/2/70	
	20	2/2/70	
	21	2/2/70	
	22	2/2/70	
	23	2/2/70	
	24	2/2/70	
	25	2/2/70	
	26	2/2/70	
	27	2/2/70	
	28	2/2/70	
	29	2/2/70	
	30	2/2/70	
	31	2/2/70	
	32	2/2/70	
	33	2/2/70	
	34	2/2/70	
	35	2/2/70	
	36	2/2/70	
	37	2/2/70	
	38	2/2/70	
	39	2/2/70	
	40	2/2/70	
	41	2/2/70	
	42	2/2/70	
	43	2/2/70	
	44	2/2/70	
	45	2/2/70	
	46	2/2/70	
	47	2/2/70	
	48	2/2/70	
	49	2/2/70	
	50	2/2/70	

Claim		Date	
Final	Original		
	51	2/2/70	
	52	2/2/70	
	53	2/2/70	
	54	2/2/70	
	55	2/2/70	
	56	2/2/70	
21	57	2/2/70	✓=
22	58	2/2/70	✓=
23	59	2/2/70	
24	60	2/2/70	
25	61	2/2/70	
26	62	2/2/70	
27	63	2/2/70	
28	64	2/2/70	
29	65	2/2/70	
30	66	2/2/70	
31	67	2/2/70	
32	68	2/2/70	
33	69	2/2/70	
34	70	2/2/70	
35	71	2/2/70	
36	72	2/2/70	
37	73	2/2/70	
38	74	2/2/70	✓✓✓
	75	2/2/70	
	76	2/2/70	
	77	2/2/70	
	78	2/2/70	
	79	2/2/70	
	80	2/2/70	
	81	2/2/70	
	82	2/2/70	
	83	2/2/70	
	84	2/2/70	
	85	2/2/70	
	86	2/2/70	
	87	2/2/70	
	88	2/2/70	
	89	2/2/70	
	90	2/2/70	
	91	2/2/70	
	92	2/2/70	
	93	2/2/70	
	94	2/2/70	
	95	2/2/70	
	96	2/2/70	
	97	2/2/70	
	98	2/2/70	
	99	2/2/70	
	100	2/2/70	